Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival

Autor: Inge G.P. Geelen, Noortje Thielen, Jeroen J.W.M. Janssen, Mels Hoogendoorn, Tanja J.A. Roosma, Sten P. Willemsen, Peter J.M. Valk, Otto Visser, Jan J. Cornelissen, Peter E. Westerweel

Publikováno v: Haematologica, Vol 102, Iss 12 (2017)

Externí odkaz: https://doaj.org/article/3935bd56b878478db2567e006e5efd9a

Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe

Autor: Jeroen Janssen, Peter J. M. Valk, Tanja J.A. Roosma, Otto Visser, Mels Hoogendoorn, Noortje Thielen, Jan J. Cornelissen, Peter E. Westerweel, Inge G.P. Geelen

Publikováno v: European Journal of Haematology, 100(4), 367-371. Wiley-Blackwell Publishing Ltd
Geelen, I G P, Thielen, N, Janssen, J J W M, Hoogendoorn, M, Roosma, T J A, Valk, P J M, Visser, O, Cornelissen, J J & Westerweel, P E 2018, ' Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe ', European Journal of Haematology, vol. 100, no. 4, pp. 367-371 . https://doi.org/10.1111/ejh.13023
European Journal of Haematology, 100(4), 367-371. Wiley-Blackwell

OBJECTIVES: The monitoring of response in chronic myeloid leukemia (CML) is of great importance to identify patients failing their treatment in order to adjust TKI choice and thereby prevent progression to advanced stage disease. Cytogenetic monitori

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f081500ce8a62bdf32b9a017624a2a4
https://hdl.handle.net/1765/104631

Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival

Autor: Noortje Thielen, Peter E. Westerweel, Otto Visser, Peter J. M. Valk, Inge G.P. Geelen, Mels Hoogendoorn, Jan J. Cornelissen, Tanja J.A. Roosma, Sten P. Willemsen, Jeroen Janssen

Publikováno v: Haematologica, 102(12), e486-e489. Ferrata Storti Foundation
Haematologica, 102(12), 486-489. Ferrata Storti Foundation
Geelen, I G P, Thielen, N, Janssen, J J W M, Hoogendoorn, M, Roosma, T J A, Willemsen, S P, Valk, P J M, Visser, O, Cornelissen, J J & Westerweel, P E 2017, ' Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival ', Haematologica, vol. 102, no. 12, pp. e486-e489 . https://doi.org/10.3324/haematol.2017.175265

The importance of adequate response monitoring during the treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) and testing for BCR-ABL1 kinase domain (KD) mutations in case of TKI failure is generally acknowledged and cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f6e1a636de7857ac7f9f27a90e96e2f
https://doi.org/10.3324/haematol.2017.175265